Impact of COVID-19 on the management of hypertension: a perspective on disease severity, service use patterns and expenditures from Ghana's health insurance claims data.

IF 2.7 4区 医学 Q2 PERIPHERAL VASCULAR DISEASE Journal of Human Hypertension Pub Date : 2024-06-20 DOI:10.1038/s41371-024-00924-3
Ama Pokuaa Fenny, Evans Otieku, Samuel Owusu Achiaw, Bernard Okoe Boye, Francis Asenso-Boadi, Vivian Addo-Cobbiah, Mariam Musah
{"title":"Impact of COVID-19 on the management of hypertension: a perspective on disease severity, service use patterns and expenditures from Ghana's health insurance claims data.","authors":"Ama Pokuaa Fenny, Evans Otieku, Samuel Owusu Achiaw, Bernard Okoe Boye, Francis Asenso-Boadi, Vivian Addo-Cobbiah, Mariam Musah","doi":"10.1038/s41371-024-00924-3","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertension is a leading cause of morbidity in Ghana and other sub-Saharan African countries, but management has historically suffered from the fragility of health systems in these countries. This has been exacerbated by the COVID-19 pandemic and its associated measures. Our study examines and quantifies the effect of the pandemic on the management of hypertension in Ghana by determining changes in disease severity and presentation, as well as changes in health service use patterns and expenditures. We used cross-sectional data to perform an impact evaluation of COVID-19 on hypertension management before and during the pandemic. We employed statistical tests including t-tests, z-tests, and exact Poisson tests to estimate and compare hypertension episode intensity and related claim expenditures before and during the pandemic using medical claims data from Ghana's National Health Insurance Authority database. The study duration includes a 12-month reference/pre-pandemic period (March 2019-February 2020) relative to the target/pandemic period (March 2020-February 2021). We observed that although there was a 20% reduction in the number of hypertension claimants in the pandemic year, there was an increase in hypertension severity as measured by the number of hypertension episodes per claimant. There was also an 18.64% or $22.88 (95% CI: $21-$25, p = 0.01042) increase in the average cost per hypertension claimant in the pandemic year. The increase in episodes per claimant had the largest financial impact on the average cost per claimant. The findings from our studies are relevant for future policymaking and strategy implementation for hypertension control in Ghana.</p>","PeriodicalId":16070,"journal":{"name":"Journal of Human Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Human Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41371-024-00924-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Hypertension is a leading cause of morbidity in Ghana and other sub-Saharan African countries, but management has historically suffered from the fragility of health systems in these countries. This has been exacerbated by the COVID-19 pandemic and its associated measures. Our study examines and quantifies the effect of the pandemic on the management of hypertension in Ghana by determining changes in disease severity and presentation, as well as changes in health service use patterns and expenditures. We used cross-sectional data to perform an impact evaluation of COVID-19 on hypertension management before and during the pandemic. We employed statistical tests including t-tests, z-tests, and exact Poisson tests to estimate and compare hypertension episode intensity and related claim expenditures before and during the pandemic using medical claims data from Ghana's National Health Insurance Authority database. The study duration includes a 12-month reference/pre-pandemic period (March 2019-February 2020) relative to the target/pandemic period (March 2020-February 2021). We observed that although there was a 20% reduction in the number of hypertension claimants in the pandemic year, there was an increase in hypertension severity as measured by the number of hypertension episodes per claimant. There was also an 18.64% or $22.88 (95% CI: $21-$25, p = 0.01042) increase in the average cost per hypertension claimant in the pandemic year. The increase in episodes per claimant had the largest financial impact on the average cost per claimant. The findings from our studies are relevant for future policymaking and strategy implementation for hypertension control in Ghana.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19 对高血压管理的影响:从加纳医疗保险报销数据透视疾病严重程度、服务使用模式和支出。
高血压是加纳和其他撒哈拉以南非洲国家的主要发病原因,但由于这些国家的卫生系统脆弱,其管理历来受到影响。COVID-19 大流行及其相关措施加剧了这一问题。我们的研究通过确定疾病严重程度和表现形式的变化,以及医疗服务使用模式和支出的变化,研究并量化了大流行对加纳高血压管理的影响。我们使用横截面数据对 COVID-19 在大流行之前和期间对高血压管理的影响进行了评估。我们采用了 t 检验、z 检验和精确泊松检验等统计检验方法,利用加纳国家健康保险管理局数据库中的医疗索赔数据,估算并比较了大流行前和大流行期间的高血压发病强度和相关索赔支出。研究期间包括 12 个月的参照期/大流行前(2019 年 3 月至 2020 年 2 月)和目标期/大流行期间(2020 年 3 月至 2021 年 2 月)。我们观察到,虽然大流行年的高血压索赔人数减少了 20%,但以每位索赔人的高血压发作次数来衡量,高血压的严重程度却有所增加。大流行年每位高血压索赔者的平均费用也增加了 18.64% 或 22.88 美元(95% CI:21-25 美元,p = 0.01042)。每位索赔者发病次数的增加对每位索赔者的平均费用产生了最大的财务影响。我们的研究结果对加纳未来的高血压控制政策制定和战略实施具有现实意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Human Hypertension
Journal of Human Hypertension 医学-外周血管病
CiteScore
5.20
自引率
3.70%
发文量
126
审稿时长
6-12 weeks
期刊介绍: Journal of Human Hypertension is published monthly and is of interest to health care professionals who deal with hypertension (specialists, internists, primary care physicians) and public health workers. We believe that our patients benefit from robust scientific data that are based on well conducted clinical trials. We also believe that basic sciences are the foundations on which we build our knowledge of clinical conditions and their management. Towards this end, although we are primarily a clinical based journal, we also welcome suitable basic sciences studies that promote our understanding of human hypertension. The journal aims to perform the dual role of increasing knowledge in the field of high blood pressure as well as improving the standard of care of patients. The editors will consider for publication all suitable papers dealing directly or indirectly with clinical aspects of hypertension, including but not limited to epidemiology, pathophysiology, therapeutics and basic sciences involving human subjects or tissues. We also consider papers from all specialties such as ophthalmology, cardiology, nephrology, obstetrics and stroke medicine that deal with the various aspects of hypertension and its complications.
期刊最新文献
Angiotensin-converting enzyme inhibitors: a therapeutic option for controlling blood pressure associated with delayed cognitive processing speed. Position statement on hypertension by Indian Society of Hypertension, 2023. Prognostic impact of fibrinogen in patients with resistant hypertension. The association of leptin and incident hypertension in the reasons for geographic and racial differences in stroke (REGARDS) cohort. Differences in ambulatory versus home blood pressure levels by ethnicity: data from the United Kingdom and Japan.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1